Table 1.
PCC cohorts stratified by the PASS algorithm.
| Study No. | First Author | Year Published | Number of PCCs * | Number of Malignant PCCs * | Definition of Malignant PCCs | Mal PCCs PASS ≥ 4 | Mal PCCs PASS < 4 | Benign PCCs PASS ≥ 4 | Benign PCCs PASS < 4 | SENS | SPEC | PPV | NPV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Thompson | 2002 | 100 | 33 | MET | 33 | 0 | 17 | 50 | 100% | 75% | 66% | 100% |
| 2 | August | 2004 | 37 | 14 | MET | 14 | 0 | 23 | 0 | 100% | 0% | 38% | 0% |
| 3 | Kajor | 2005 | 40 | 1 | MET | 1 | 0 | 7 | 32 | 100% | 82% | 13% | 100% |
| 4 | Strong | 2008 | 47 | 5 | MET | 5 | 0 | 10 | 32 | 100% | 76% | 33% | 100% |
| 5 | Agarwal | 2010 | 90 | 6 | MET/DO | 5 | 1 | 27 | 57 | 83% | 68% | 16% | 98% |
| 6 | Szalat | 2010 | 26 | 7 | MET | 6 | 1 | 0 | 19 | 86% | 100% | 100% | 95% |
| 7 | de Wailly | 2012 | 21 | 7 | MET | 7 | 0 | 7 | 7 | 100% | 50% | 50% | 100% |
| 8 | Mlika | 2013 | 11 | 2 | MET | 2 | 0 | 6 | 3 | 100% | 33% | 25% | 100% |
| 9 | Bialas | 2013 | 62 | 5 | REC/MET | 5 | 0 | 29 | 28 | 100% | 49% | 15% | 100% |
| 10 | Ocal | 2014 | 11 | 3 | REC | 3 | 0 | 4 | 4 | 100% | 50% | 43% | 100% |
| 11 | Kulkarni | 2016 | 6 | 1 | MET | 1 | 0 | 2 | 3 | 100% | 60% | 33% | 100% |
| 12 | Lupşan | 2016 | 17 | 13 | MET | 13 | 0 | 2 | 2 | 100% | 50% | 87% | 100% |
| 13 | Suenaga | 2016 | 1 | 0 | REC | 0 | 0 | 1 | 0 | npd | npd | npd | npd |
| 14 | Kim | 2016 | 90 | ns | REC/MET | npd | 0 | npd | 52 | npd | npd | npd | npd |
| 15 | Maignan | 2017 | 65 | 0 | MET | 0 | 0 | 9 | 56 | npd | 86% | npd | npd |
| 16 | Koh | 2017 | 32 | 4 | MET | 3 | 1 | 19 | 9 | 75% | 32% | 14% | 90% |
| 17 | Aggeli | 2017 | 69 | 0 | MET | ns | ns | 31 | 37 | npd | 54% | npd | npd |
| 18 | Stenman | 2018 | 41 | 0 | REC/MET | 0 | 0 | 10 | 31 | npd | 76% | npd | npd |
| 19 | Muchuweti | 2018 | 1 | 0 | MET | 0 | 0 | 1 | 0 | npd | npd | npd | npd |
| 20 | Stenman | 2018 | 81 | 4 | REC/MET | 4 | 0 | 19 | 58 | 100% | 75% | 17% | 100% |
| Summarized | - | 848 | 105 | - | 102 | 3 | 224 | 480 | 97% | 68% | 31% | 99% | |
MET—metastatic disease, REC—recurrence, DO—direct overgrowth, ns—not specified, npd—not possible to determin, SENS—sensitivity, SPEC—specificity, PPV—positive predictive value, NPV—negative predictive value; *—Numbers correspond to cases histologically investigated, which is not necessarily identical to cases included in the study as a whole. Numbers in bold script at the bottom represent summarized values for all parameters, with corresponding SENS, SPEC, PPV and NPV values calculated for these sums.